Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors. Issue 3 (5th November 2013)

• Record Type: Journal Article
• Authors: Wang, Xin Shelley; Zhao, Fengmin; Fisch, Michael J.; O'Mara, Ann M.; Cella, David; Mendoza, Tito R.; Cleeland, Charles S.
• Is Part Of: Cancer. Volume 120:Issue 3(2014)
• Page Start: 425
• Page End: 432
• Publication Date: 2013-11-05
• Subjects: fatigue -- patient‐reported outcome -- practice guidelines -- M. D. Anderson Symptom Inventory (MDASI) -- survivorship; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28434
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: The effective management of fatigue in patients with cancer requires a clear delineation of what constitutes nontrivial fatigue. The authors defined numeric cutpoints for fatigue severity based on functional interference and described the prevalence and characteristics of fatigue in patients with cancer and survivors. METHODS: In a multicenter study, outpatients with breast, prostate, colorectal, or lung cancer rated their fatigue severity and symptom interference with functioning on the M. D. Anderson Symptom Inventory numeric scale of 0 to 10. Ratings of symptom interference guided the selection of numeric rating cutpoints between mild, moderate, and severe fatigue levels. Regression analysis identified significant factors related to reporting moderate/severe fatigue. RESULTS: The statistically optimal cutpoints were ≥ 4 for moderate fatigue and ≥ 7 for severe fatigue. Moderate/severe fatigue was reported by 983 of 2177 patients (45%) undergoing active treatment and was more likely to occur in patients receiving treatment with strong opioids (odds ratio [OR], 3.00), those with a poor Eastern Cooperative Oncology Group performance status (OR, 2.00), those who had > 5% weight loss within 6 months (OR, 1.60), those who were receiving > 10 medications (OR, 1.58), those with lung cancer (OR, 1.55), and those with a history of depression (OR, 1.42). Among survivors (patients with complete remission or no evidence of disease, and not currently receiving cancer treatment), 29% of patients (150 of 515 patients) had moderate/severe fatigue that was associated with poor performance status (OR, 3.48) and a history of depression (OR, 2.21). CONCLUSIONS: The current study statistically defined fatigue severity categories related to significantly increased symptom interference. The high prevalence of moderate/severe fatigue in both actively treated patients with cancer and survivors warrants the promoting of the routine assessment and management of patient‐reported fatigue. Cancer 2014;120:425–432 . © 2013 American Cancer Society . Abstract : Fatigue remains a ubiquitous problem in cancer care, and management options are inadequate. The authors sought to establish statistically derived cutpoints for clinically significant fatigue in patients with cancer and survivors and to produce a fatigue severity profile using these cutpoints. The results of the current study provide empirical evidence supporting current management guidelines for clinical fatigue.